PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 21535912-6 2012 Our aim was to verify whether the success of human myoblast transplantation in immunodeficient dystrophic mice is enhanced with losartan, a molecule that downregulates TGF-beta expression. Losartan 128-136 transforming growth factor, beta 1 Mus musculus 168-176 24355923-7 2014 Importantly, suppression of Smad2 phosphorylation and TGF-beta1 expression correlated with the therapeutic efficacy of the angiotensin II type 1 receptor antagonist losartan. Losartan 165-173 transforming growth factor, beta 1 Mus musculus 54-63 23868934-8 2013 In contrast, the increased Tgfb1 expression and adventitial phospho-Smad2 staining were only partially attenuated by losartan. Losartan 117-125 transforming growth factor, beta 1 Mus musculus 27-32 23780535-11 2013 These results suggest that blocking the expression of transforming growth factor (TGF)-beta1 with losartan improves the effect of PRP therapy on muscle healing after a contusion injury. Losartan 98-106 transforming growth factor, beta 1 Mus musculus 54-92 22698430-5 2013 When losartan plus atorvastatin was administered, significant changes in the serum concentration and mRNA expression, including the increase of tPA and the decrease of TGF-beta1 and PAI-1, were observed compared with those in other groups. Losartan 5-13 transforming growth factor, beta 1 Mus musculus 168-177 22698430-6 2013 CONCLUSIONS: Our findings suggest that the simultaneous application of losartan and atorvastatin leads to an enhanced reduction in adhesion bands more than that of HA/CMC treatment, compared with the control group, possibly through balancing the expression of TGF-beta1, tPA, and PAI-1. Losartan 71-79 transforming growth factor, beta 1 Mus musculus 260-269 22943509-2 2012 Antagonists of the angiotensin II receptor type 1 (AT1), including the anti-hypertensive drug losartan, have been shown to block also the profibrotic action of transforming growth factor (TGF)-beta and thereby ameliorate disease progression in mouse models of Marfan syndrome. Losartan 94-102 transforming growth factor, beta 1 Mus musculus 188-197 22522482-6 2012 Losartan"s effects on transforming growth factor beta (TGF-beta) and mitogen-activated protein kinase (MAPK) signaling pathways were evaluated with Western blotting, immunofluorescence, and cytokine measurements. Losartan 0-8 transforming growth factor, beta 1 Mus musculus 55-63 22522482-8 2012 Administration of losartan inhibited TGF-beta signaling pathway, resulting in decreased serum TGF-beta1 level and reduced downstream phosphorylated (P) Smad2/3 proteins. Losartan 18-26 transforming growth factor, beta 1 Mus musculus 37-45 22522482-8 2012 Administration of losartan inhibited TGF-beta signaling pathway, resulting in decreased serum TGF-beta1 level and reduced downstream phosphorylated (P) Smad2/3 proteins. Losartan 18-26 transforming growth factor, beta 1 Mus musculus 94-103 22522482-9 2012 Moreover, losartan activated Smad7 protein, a key negative regulator of TGF-beta signaling. Losartan 10-18 transforming growth factor, beta 1 Mus musculus 72-80 22522482-11 2012 INTERPRETATION: Losartan, a commonly prescribed US Food and Drug Administration-approved medication for hypertension, demonstrated clinical improvement and amelioration of fibrosis in the dy(2J) /dy(2J) mouse model of MDC1A via TGF-beta and MAPK signaling pathways. Losartan 16-24 transforming growth factor, beta 1 Mus musculus 228-236 21152098-2 2010 When neutralizing antibodies to TGF-beta1 or the angiotensin II inhibitor losartan were used to reduce TGF-beta1 signaling, muscle morphology and function were restored in mouse models of Marfan Syndrome and muscular dystrophy. Losartan 74-82 transforming growth factor, beta 1 Mus musculus 103-112 22479508-10 2012 Losartan significantly attenuated the expression of TGF-beta1 and Snail, and decreased kidney fibrosis induced by IS and PCS in vivo. Losartan 0-8 transforming growth factor, beta 1 Mus musculus 52-61 21134900-7 2011 Atrial myocyte-induced expression of TGF-beta1, CTGF and COL1A1 in atrial fibroblasts was attenuated by co-treatment with the Ang II receptor blocker, losartan, and apocynin. Losartan 151-159 transforming growth factor, beta 1 Mus musculus 37-46 22348081-0 2012 Losartan slows pancreatic tumor progression and extends survival of SPARC-null mice by abrogating aberrant TGFbeta activation. Losartan 0-8 transforming growth factor, beta 1 Mus musculus 107-114 22348081-6 2012 Given these results, we performed a survival study to assess the contribution of increased TGFbeta1 activity to tumor progression in SPARC-null mice using losartan, an angiotensin II type 1 receptor antagonist that diminishes TGFbeta1 expression and activation in vivo. Losartan 155-163 transforming growth factor, beta 1 Mus musculus 226-234 22348081-9 2012 In addition, losartan abrogated TGFbeta induced gene expression, reduced local invasion and metastasis, decreased vascular permeability and altered the immune profile of tumors grown in SPARC-null mice. Losartan 13-21 transforming growth factor, beta 1 Mus musculus 32-39 22783312-5 2011 Most importantly, TGF-beta antagonism through angiotensin II type 1 receptor blockers (ARBs), for example losartan, has been shown to prevent and possibly reverse aortic root dilatation in a mouse model of MFS. Losartan 106-114 transforming growth factor, beta 1 Mus musculus 18-26 16601194-3 2006 We show that aortic aneurysm in a mouse model of MFS is associated with increased TGF-beta signaling and can be prevented by TGF-beta antagonists such as TGF-beta-neutralizing antibody or the angiotensin II type 1 receptor (AT1) blocker, losartan. Losartan 238-246 transforming growth factor, beta 1 Mus musculus 125-133 20933212-5 2010 Furthermore, interventions targeting towards TGF-beta signaling using losartan, which may represent a suitable therapeutic option for AAs, were subject to skepticism especially because of conflicting experimental results obtained from TGF-beta antibody treatment without knowledge of the underlying mechanism. Losartan 70-78 transforming growth factor, beta 1 Mus musculus 45-53 18630721-13 2008 In transgenic mouse models it was shown that losartan, an angiotensin II type 1 receptor with known inhibiting effects on TGFbeta, rescues the aortic phenotype. Losartan 45-53 transforming growth factor, beta 1 Mus musculus 122-129 20112290-7 2010 High glucose or ANG II also synergistically increased transforming growth factor-beta1 (TGF-beta(1)) expression, while pretreatment with losartan abolished the high glucose-induced increase in TGF-beta(1) production. Losartan 137-145 transforming growth factor, beta 1 Mus musculus 193-204 19635970-2 2009 Recent evidence suggests that losartan, an angiotensin II type 1 blocker that blunts TGF-beta activation, may be an effective treatment for MFS. Losartan 30-38 transforming growth factor, beta 1 Mus musculus 85-93 19635970-8 2009 Losartan-treated Fbn1(C1039G/+) mice had lower total TGF-beta1 concentrations compared with age-matched Fbn1(C1039G/+) mice treated with placebo (P=0.01; n=18; 90+/-5 ng/mL), and circulating total TGF-beta1 levels were indistinguishable from those of age-matched wild-type mice (P=0.8). Losartan 0-8 transforming growth factor, beta 1 Mus musculus 53-62 19635970-8 2009 Losartan-treated Fbn1(C1039G/+) mice had lower total TGF-beta1 concentrations compared with age-matched Fbn1(C1039G/+) mice treated with placebo (P=0.01; n=18; 90+/-5 ng/mL), and circulating total TGF-beta1 levels were indistinguishable from those of age-matched wild-type mice (P=0.8). Losartan 0-8 transforming growth factor, beta 1 Mus musculus 197-206 19635970-12 2009 CONCLUSIONS: Circulating TGF-beta1 concentrations are elevated in MFS and decrease after administration of losartan, beta-blocker therapy, or both and therefore might serve as a prognostic and therapeutic marker in MFS. Losartan 107-115 transforming growth factor, beta 1 Mus musculus 25-34 17237794-7 2007 Systemic antagonism of TGF-beta through administration of TGF-beta-neutralizing antibody or the angiotensin II type 1 receptor blocker losartan normalizes muscle architecture, repair and function in vivo. Losartan 135-143 transforming growth factor, beta 1 Mus musculus 23-31 16601194-3 2006 We show that aortic aneurysm in a mouse model of MFS is associated with increased TGF-beta signaling and can be prevented by TGF-beta antagonists such as TGF-beta-neutralizing antibody or the angiotensin II type 1 receptor (AT1) blocker, losartan. Losartan 238-246 transforming growth factor, beta 1 Mus musculus 125-133 15487702-12 2004 Finally, AngII-mediated increase in TGF-beta mRNA was inhibited by losartan, AG1478, LY249002, and U0126. Losartan 67-75 transforming growth factor, beta 1 Mus musculus 36-44 15496155-15 2004 The albumin-mediated increase in type II TGF-beta receptor mRNA was attenuated in the presence of 1 micromol/L losartan, suggesting involvement of a local renin-angiotensin system. Losartan 111-119 transforming growth factor, beta 1 Mus musculus 41-49 31611175-8 2019 Importantly, the regulatory effects of miR-21 knockdown and the angiotensin type 1 receptor blocker losartan alone or in combination on the PPARalpha/TGF-beta1/Smad3 pathway in Ang II-treated cells were almost the same. Losartan 100-108 transforming growth factor, beta 1 Mus musculus 150-159 11171784-12 2001 CONCLUSIONS: Treatment with losartan reversed interstitial fibrosis and the expression of collagen 1alpha (I) and transforming growth factor-beta1 in the hearts of cTnT-Q(92) mice. Losartan 28-36 transforming growth factor, beta 1 Mus musculus 90-146 34094856-0 2021 Losartan protects against osteoarthritis by repressing the TGF-beta1 signaling pathway via upregulation of PPARgamma. Losartan 0-8 transforming growth factor, beta 1 Mus musculus 59-68 34094856-11 2021 Losartan treatment or PPARgamma activation contributes to reduced levels of IL-6, IL-1beta, TNF-alpha, and COX-2, expression of TGF-beta1, MMP-13, ADAMTS-4, ADAMTS-5, HtrA1, and iNOS, along with reduced Smad2 and Smad3 phosphorylation, but elevated PPARgamma and Collagen II expression in vivo and in vitro. Losartan 0-8 transforming growth factor, beta 1 Mus musculus 128-137 34094856-13 2021 Conclusion: Our results show that losartan could arrest the progression of OA by upregulating PPARgamma expression and inactivating the TGF-beta1 signaling pathway.The translational potential of this article: Our results provide a biological rationale for the use of losartan as a potential candidate for OA treatment. Losartan 34-42 transforming growth factor, beta 1 Mus musculus 136-145 10840457-10 2000 In animals treated with losartan, kidney TGF-beta, IFN-gamma and IL-6 decreased significantly at 3 and 8 weeks as compared with controls, untreated or those treated with NaCl, (p <0.005 respectively). Losartan 24-32 transforming growth factor, beta 1 Mus musculus 41-49 30610922-0 2019 Losartan attenuates progression of osteoarthritis in the synovial temporomandibular and knee joints of a chondrodysplasia mouse model through inhibition of TGF-beta1 signaling pathway. Losartan 0-8 transforming growth factor, beta 1 Mus musculus 156-165 31284709-5 2019 Mice treated with galunisertib or losartan barely exhibited phosphorylated Smad2, suggesting that both drugs effectively blocked overactivated canonical TGFbeta signaling in Fbn1C1039G/+ mice. Losartan 34-42 transforming growth factor, beta 1 Mus musculus 153-160 30610922-2 2019 The purpose of this study was to explore the ability of Losartan to inhibit the inflammatory signaling pathway of TGF-beta1 observed during osteoarthritic progression in the temporomandibular joint (TMJ) and knee joint using a genetic mouse model. Losartan 56-64 transforming growth factor, beta 1 Mus musculus 114-123 30610922-9 2019 Decreased expression of HtrA1, a key regulator to the TGF-beta1 signaling pathway, was demonstrated in vitro as well as in vivo, via Losartan inhibition. Losartan 133-141 transforming growth factor, beta 1 Mus musculus 54-63 26758229-8 2016 Mechanism study showed the declination of collagen I level via losartan was caused by inhibition of active transforming growth factor-beta1. Losartan 63-71 transforming growth factor, beta 1 Mus musculus 107-139 28768908-4 2017 Informatively, TGF-beta, angiotensin II type 1 receptor (AT1R), or ERK antagonism (with neutralizing antibody, losartan, or MEK inhibitor, respectively) prevents load-induced cardiac decompensation in MFS mice, despite persistent PO. Losartan 111-119 transforming growth factor, beta 1 Mus musculus 15-23 27389178-0 2017 Losartan improves cerebrovascular function in a mouse model of Alzheimer"s disease with combined overproduction of amyloid-beta and transforming growth factor-beta1. Losartan 0-8 transforming growth factor, beta 1 Mus musculus 132-164 27389178-5 2017 Our results are the first to demonstrate the capacity of losartan to improve cerebrovascular reactivity in an Alzheimer"s disease mouse model of combined Abeta-induced vascular oxidative stress and transforming growth factor-beta1-mediated vascular fibrosis. Losartan 57-65 transforming growth factor, beta 1 Mus musculus 198-230 28323879-14 2017 Immunohistochemistry and western blot for p-SMAD2/3 validated the inhibitory effect of losartan on TGF-beta signaling in miR-181a1/b1-/- mice. Losartan 87-95 transforming growth factor, beta 1 Mus musculus 99-107 27501834-2 2016 HYPOTHESIS: The transplantation of MDSCs in the presence of a transforming growth factor beta1 (TGF-beta1) antagonist (losartan) would result in decreased scar tissue formation and enhance muscle regeneration after contusion injuries in a mouse model. Losartan 119-127 transforming growth factor, beta 1 Mus musculus 62-94 27501834-2 2016 HYPOTHESIS: The transplantation of MDSCs in the presence of a transforming growth factor beta1 (TGF-beta1) antagonist (losartan) would result in decreased scar tissue formation and enhance muscle regeneration after contusion injuries in a mouse model. Losartan 119-127 transforming growth factor, beta 1 Mus musculus 96-105 30420805-7 2018 In addition, losartan decreased oxidative stress damage and inhibited the transforming growth factor (TGF)-beta1/Smad pathway. Losartan 13-21 transforming growth factor, beta 1 Mus musculus 74-112 30420805-8 2018 Furthermore, consistent changes were detected in vitro where losartan markedly inhibited the EMT and TGF-beta1/Smad pathway induced by high glucose in glomerular endothelial cells. Losartan 61-69 transforming growth factor, beta 1 Mus musculus 101-110 30420805-9 2018 Together, these results suggested that losartan could alleviate the EMT in glomeruli via inhibition of oxidative stress damage and the TGF-beta1/Smad signaling pathway under hyperglycemia. Losartan 39-47 transforming growth factor, beta 1 Mus musculus 135-144 26194911-4 2015 Based on the findings that TGF-beta activity is elevated in injured RDEB skin, we targeted TGF-beta activity with losartan in a preclinical setting. Losartan 114-122 transforming growth factor, beta 1 Mus musculus 27-35 26194911-4 2015 Based on the findings that TGF-beta activity is elevated in injured RDEB skin, we targeted TGF-beta activity with losartan in a preclinical setting. Losartan 114-122 transforming growth factor, beta 1 Mus musculus 91-99 26867195-9 2016 We hypothesize that systemically elevated TGF-beta1 as a result of CCl4-induced liver injury causes skeletal muscle injury, while losartan promotes muscle repair from injury via blockade of TGF-beta1 signaling. Losartan 130-138 transforming growth factor, beta 1 Mus musculus 190-199 25556973-9 2015 Finally, exogenous TGFbeta was able to restore high proliferative activity to W20-17 cells that were treated with both Ang II and losartan. Losartan 130-138 transforming growth factor, beta 1 Mus musculus 19-26 25766329-2 2015 Our previous study showed treatment with Losartan, an angiotensin II type I receptor antagonist, improved muscle strength and reduced fibrosis through transforming growth factor beta (TGF-beta) and mitogen-activated protein kinases (MAPK) signaling inhibition in the dy(2J)/dy(2J) mouse model of MDC1A. Losartan 41-49 transforming growth factor, beta 1 Mus musculus 184-192 25766329-8 2015 Thus, along with TGF-beta and MAPK signaling, NFkappaB serves as an important regulatory pathway which following Losartan treatment promotes survival in the dy(2J)/dy(2J) mouse model of MDC1A. Losartan 113-121 transforming growth factor, beta 1 Mus musculus 17-25